Project Grant R43AI197548
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $302K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35203, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $600,000 to Zylo Therapeutics, Inc. on September 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a nitric oxide-releasing microparticle formulation for topical treatment of chronic rhinosinusitis. Chronic rhinosinusitis, characterized by persistent inflammation and infection of the nasal cavity and paranasal sinuses, affects approximately 13 million U.S. adults....
- The National Institute of Allergy and Infectious Diseases awarded Duke University $194,201 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosally active biomaterial immunomodulators for chronic rhinosinusitis with nasal polyps. The project will design a non-invasive, targeted nanomaterial immunotherapy platform capable of delivering neutralization of thymic stromal lymphopoietin (TSLP), a key mediator of chronic rhinosinusitis with...
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $427,313 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate tertiary lymphoid structures in eosinophilic chronic rhinosinusitis with nasal polyps. The research examines the mechanisms of type 2 inflammation in this recalcitrant disease and the basis of disease recurrence following discontinuation of dupilumab therapy. The central hypothesis...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $240,000 on July 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the pathogenic role of the OX40/OX40 ligand axis in chronic rhinosinusitis. The research tests the hypothesis that OX40/OX40L signaling drives pathogenic inflammation in chronic rhinosinusitis (CRS), a heterogeneous upper airway disease affecting up to 12 percent of Americans and prompting...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $828,519 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 1, 2026, to investigate the integrated role of nasal airway and gut microbiome dynamics in allergic rhinitis development. The research will longitudinally sequence both nasal airway and gut metagenomes in infants from the ongoing 43rd Multicenter Airway Research Collaboration (MARC-43) cohort—a...
- The National Institute of Allergy and Infectious Diseases awarded St. Jude Children's Research Hospital Inc. $151,040 on March 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on strategies and consequences of polymicrobial nasal colonization. The research investigates how polymicrobial interactions within the upper respiratory tract impact a pathogen's ability to colonize and cause infection. The project focuses on how respiratory pathogens...
- The National Institute of Allergy and Infectious Diseases awarded $843,568 to the University of Pennsylvania on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support mechanistic research on bitter taste receptors in chronic rhinosinusitis pathogenesis and treatment. The award funds a five-year project (performance period through May 31, 2031) based in Philadelphia, Pennsylvania, investigating how bitter taste receptors—a family of G-protein-coupled...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $263,895 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the pathophysiology of invasive fungal sinusitis, a severe fungal infection affecting immunocompromised patients. The research will examine the mechanisms of fungal invasion and mucosal barrier degradation in invasive fungal sinusitis, with focus on fungal virulence, matrix metalloproteinase...
- The National Institute of Allergy and Infectious Diseases awarded $762,758 to the Board of Regents of the University of Nebraska, acting through its University of Nebraska Medical Center division in Omaha, Nebraska, on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient is developing bioengineered 3D bioprinted scaffolds to treat Staphylococcus aureus biofilm infections following craniotomy procedures. The scaffolds employ two delivery...